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Lung involvement at presentation predicts
disease activity and permanent organ damage at
6, 12 and 24 months follow − up in ANCA −
associated vasculitis
Tidi M Hassan*, Astrid S Hassan, Ann Igoe, Mark Logan, Cedric Gunaratnam, Noel G McElvaney and Shane J O’Neill
Abstract
Background: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may present with pulmonary
involvement ranging from mild to life-threatening disease such as diffuse alveolar hemorrhage. There is a paucity of
information regarding morbidity outcomes for AAV subjects presenting with lung involvement. This study determines
the relationship between disease activity and damage in these subjects using the Birmingham Vasculitis Activity Score
v 3 (BVAS 3) and Vasculitis Damage Index (VDI) respectively.
Results: 151 patients with AAV were included with 59 presenting initially with pulmonary involvement. The initial BVAS
scores recorded at time of diagnosis were positively correlated with the final VDI scores at 24 months (p < 0.0001,
rs = 0.5871). No differences between BVAS and VDI scores were seen for both groups, however in the lung-involvement
group only, BVAS scores were significantly higher at 6, 12 and 24 months whilst the VDI scores were significantly higher
at 12 and 24 months. Subjects presenting with pulmonary involvement had an increased likelihood for cardiovascular
(OR 1.31, 95% CI 0.89, 1.54; p = 0.032) and renal (OR 1.32, 95% CI 1.22, 1.39; p = 0.005) involvement. Subjects presenting
with lung involvement with granulomatosis with polyangiitis and microscopic polyangiitis had 24-month VDI scores
that were significantly higher (p = 0.027, p = 0.045), and more likely to develop pulmonary fibrosis (OR 1.79, 95% CI 1.48,
2.12; p < 0.001).
Conclusion: AAV subjects with lung involvement at presentation had a higher disease activity and damage scores at 6,
12 and 24 months follow-up representing a considerable burden of disease despite improvement in overall survival
due to the introduction of immunosuppressive therapy.
Keywords: ANCA, Vasculitis, Pulmonary hemorrhage
Background
Antineutrophilic cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a potentially life-threatening condition
[1]. The introduction of immunosuppressive therapy has
transformed this condition from an outcome of 80%
mortality at one year to a survival of 55% and 75% in
microscopic polyangiitis (MPA) and granulomatosis with
polyangiitis (GPA) respectively at 10 years [2,3]. Very ac-
tive disease at presentation, continuous disease activity, re-
lapse and drug toxicity may cause irreversible damage
leading to considerable burden of disease. Therefore, stud-
ies to stratify prognostic indicators of AAV and identify
high-risk subjects are crucial [4,5].
Pulmonary involvement (PI) is a major characteristic
feature of both GPA and Churg-Strauss syndrome (CS),
but less common in MPA [6]. Diffuse alveolar hemorrhage
(DAH) is one of the most severe pulmonary manifesta-
tions. The prognostic value of PI in AAV remains contro-
versial. One study reported that DAH at presentation in
MPA was associated with a relative risk (RR) of 8.65 for
mortality [7]. Reinhold-Keller reported that PI was associ-
ated with a RR of 3.75 for mortality in GPA [8]. Another
study showed that the early death risk was 15 times higher
* Correspondence: tidihassan@rcsi.ie
Department of Respiratory, Beaumont Hospital, Beaumont Road, Dublin 9,
Ireland
© 2014 Hassan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Hassan et al. BMC Immunology 2014, 15:20
http://www.biomedcentral.com/1471-2172/15/20
in subjects presenting with cough in GPA [9]. However, a
more recent study concluded that DAH alone is not pre-
dictive of a poor prognosis [10]. Meanwhile, the revised
Five-Factor Score (FFS), a score designed to predict sur-
vival concluded that ENT manifestations were associated
with favorable outcomes in GPA [11].
Although survival rates have improved, disease activity
and subsequent burden of disease remain important out-
comes in assessing the overall well being of AAV indi-
viduals. The objective of this study was to determine the
relationship between disease activity and damage in sub-
jects presenting with PI and lung involvement (LI) using
the Birmingham Vasculitis Activity Score v.3 (BVAS3)
and Vasculitis Damage Index (VDI) respectively.
Methods
Patient selection
We enrolled 151 subjects with AAV including GPA,
MPA and CS into this study from a single tertiary center
in Dublin, Ireland. The study was discussed with Beau-
mont Hospital Research Ethics Committee who waived
the need for ethical approval. The diagnoses satisfied the
American College of Rheumatology (ACR) criteria and/
or the Chapel Hill Consensus nomenclature [12]. These
adult subjects were recruited from either the pulmonol-
ogy, rheumatology, nephrology or dermatology clinic
from July 2008 to June 2012. No written informed con-
sent was obtained as the BVAS and VDI scores were
performed routinely.
Data collection
Subjects’ demographics, initial symptoms, date of diagno-
sis, physical examination findings, ANCA levels, blood
biochemistry, diagnostic imaging, relapses and treatment
regimens were recorded. Relapses are defined within the
newly developed clinical finding of GPA and adapted to
the diseases according to BVAS definition [6]. Cytoplasmic
or proteinase 3(c-/PR3) and perinuclear or myeloperoxi-
dase (p-/MPO) ANCA were measured at the same time
point using ELISA. Biopsies including renal, skin, nasal
and pulmonary showing capillaritis confirmed the AAV
diagnosis, when needed.
All subjects with PI at initial presentation were followed
up in the pulmonology clinic with pulmonary function
test and chest radiograph at 3-,6-, 12-month and 2-year
follow-up. The BVAS3 was calculated at 0-, 6-, 12-month
and 2-year follow-up while the VDI was calculated at 6-,
12-month and 2-year. Both BVAS3 and VDI scores be-
tween 0- and 6-months of ANCA-vasculitis diagnosed
before June 2009 were scored retrospectively from hos-
pital charts and radiological investigations. BVAS3 and
VDI were recorded at 12-month and 2-year prospectively.
For subjects diagnosed after June 2009 (n = 94), data were
collected prospectively. Intraobserver reliability of BVAS
and VDI was examined in all subjects with a second as-
sessment by the same observer within the same week of
the first assessment. Interobserver reliability was evaluated
in 20 subjects independently assessed by two observers on
the same day. We also examined the chest radiograph or
CT thorax performed within two weeks of initial clinical
presentation. All subjects had at least one chest radio-
graph within a month of their initial presentation.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 5 software package (San Diego, CA). Correlation
of BVAS3 and VDI scores was analyzed by the Spearman
correlation test. Differences were analyzed by the Student
t-test (non-parametric, one-tailed; Mann Whitney) as ap-
propriate. In multivariate analyses, the prevalence odds
ratio (OR) with 95% confidence interval (CI) for the asso-
ciation between VDI and clinical presentation was esti-
mated using logistic regression.
Results
Patient demographics
The dataset included 151 subjects; 6 subjects had data
which was unattainable for at least 1 variable. 51 with
GPA, 58 with MPA, 9 with CS and 21 with polyarteritis
nodosa (PAN) are included as the majority of subjects in
this analysis. 2 subjects were diagnosed with idiopathic
pauci-immune pulmonary capillaritis (IPIPC). Table 1
shows the main characteristics for the overall study
population with and without PI. Mean age at diagnosis
was 45 ± 11.2 years. Mean (SD) follow-up was 2.22 years
and there were 8 deaths. Subjects that did not present
with PI had a significantly higher rate of relapse com-
pared to those who did (p < 0.05).
PI at initial presentation was present in 59 subjects. 14
subjects had overlapping pulmonary diseases involving
either endobronchial or parenchymal disease at initial
presentation. Subjects with PI at initial presentation ex-
hibit higher mortality than non-PI subjects (6.8 vs 4.3)
however this was not statistically significant. All 8 sub-
jects who died on this study had a VDI of >4. 4 subjects
with active vasculitis died due to sepsis and multi-organ
failure. The other 4 deaths were due to cardiac arrest
from active renal disease, a myocardial infarction due to
long-standing coronary artery disease and 2 died from
respiratory failure secondary to bronchopneumonia. No
subjects died due to primary active disease in the lungs.
Malignancy was not observed in any patient.
Serum blood test at initial presentation
The mean (SD) serum creatinine was 204 ± 145 uM at
time of diagnosis. The mean (SD) serum creatinine was
higher in subjects with non-PI at 251 ± 161 uM com-
pared to 176 ± 139 in subjects with PI. 14 subjects in the
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PI group were diagnosed as having pulmonary-renal syn-
dromes. ANCA levels were positive in all subjects. PR3
ANCA was the major ANCA for the PI group while
MPO ANCA was more common with no PI. 58% of
subjects had PR3 ANCA of more than 20 U/ml in the PI
group compared to 27% in the non-PI group. High titres
of MPO ANCA of more than 20 U/ml were predomin-
antly seen in the group with non-PI.
BVAS and VDI at 0, 6, 12 and 24 months
Both the BVAS3 and VDI scores at initial presentation
did not correlate with the number of subsequent re-
lapses and the type of immunosuppressive therapy
employed within 2 months of initial presentation. The
initial BVAS scores recorded at time of diagnosis were
found to be positively correlated with the final VDI
scores at 24 months (p < 0.0001, rs = 0.5871) (Figure 1).
This was also observed in subjects with PI only (p =
0.0049, rs = 0. 3615). Whilst there were no differences
between BVAS and VDI scores for both patient groups,
differences were seen when the PI subjects were subca-
tegorized into LI group, accounting for subjects that
only had pathology in either the lung parenchyma, air-
ways, pleura and pulmonary arteries. BVAS3 scores were
significantly higher in subjects with LI at 6, 12 and
24 months of follow-up (Figure 2A). The initial BVAS
scores were also significantly higher in subjects present-
ing with LI (Additional file 1: Figure S1). The VDI re-
corded at 6, 12 and 24 months were higher in subjects
with initial LI with differences significant for month 12
and 24 (Figure 2B).
At baseline, subjects with PI were more likely to have
general systemic features and musculoskeletal involve-
ment compared to those without PI (OR 1.32; 95% CI
1.11,1,59; p = 0.032, OR 1.62; 95% CI 1.15,2.31; p =
<0.001 respectively) (Table 2). Subjects presenting with
PI had an increased likelihood of cardiovascular (OR
1.31, 95% CI 0.89,1.54; p = 0.032) and renal (OR 1.32,
95% CI 1.22, 1.39, p = 0.005) involvement. Both groups
had an average of 3 organ systems involved at the time
of diagnosis.
Types of pulmonary manifestations and AAV phenotype
17 and 6 subjects presented with nasal diseases and sub-
glottic stenosis respectively (Figure 3). 13 subjects pre-
sented with endobronchial diseases including airway
obstruction, segmental bronchial wall thickening, tra-
cheal wall abnormalities and bronchiectasis. 1 patient
had ulcerating upper airway disease. 4 subjects who de-
veloped chronic asthma were both diagnosed with CS. 2
subjects presented with pleural nodules on chest radio-
graph. Both had overlapping presentation with nasal dis-
eases and parenchymal disease. 29 subjects presented
with parenchymal disease in which 12 presented with
DAH. 11 presented with pulmonary nodules whilst 9
presented with cavitating lesions with overlapping fea-
tures. These subjects were exclusively diagnosed with ei-
ther GPA or MPA.
When LI subjects were categorized based on their
diagnoses, GPA and MPA had a final VDI score that was
significantly higher than their non-LI and PI counter-
parts with the same diagnosis (Figure 4). At 2-year
follow-up, subjects with LI were also more likely to de-
velop pulmonary fibrosis (OR 1.79; 95% CI 1.48, 2.12;
p < 0.001) and impaired lung function (OR 1.42; 95% CI
1.27, 1.84; p = 0.045) (Table 3). 4 out of 12 subjects pre-
senting with DAH developed pulmonary fibrosis. When
the different lung function parameters were assessed,
only diffusing capacity for carbon monoxide corrected to
Table 1 Baseline demographic and clinical characteristics
with anti-neutrophil cytoplasmic antibody (ANCA)
associated vasculitis (AAV), within subgroups with
pulmonary and non-pulmonary involvement at initial
presentation of AAV
Patient characteristics Pulmonary
involvement
Non-pulmonary
involvement
(n = 59) (n = 92)
Age, mean +/− SD years 43 +/− 12.9 49 +/1 10.1
Male sex, n (%) 29 (49) 49 (53)
AAV diagnosis, n (%)
GPA 38 (64.4) 13 (14.1)
MPA 9 (15.3) 49 (53.3)
CS 5 (8.5) 4 (4.3)
PAN 4 (6.7) 17 (18.5)
Others 3 (5.1) 9 (9.8)
Mean serum creatinine, uM (SD) 176 +/− 139 251 +/− 161
ANCA positivity, n (%)
MPO ANCA 17 (29) 58 (63)
PR3 ANCA 45 (76) 41 (45)
Relapses 12 (20.3) 25 (27)
1-Relapse 7 (11.8) 15 (16.3)
2-Relapse 1 (1.7) 3 (3.3)
3-Relapse 1 (1.7) 3 (3.3)
> 3-relapse 3 (5.1) 4 (4.3)
Immunosuppressive therapy within
2 months of intial presentation, n (%)
Cyclophosphamide 26 (44) 59 (62)
Glucocorticoids 29 (49) 65 (70)
Azathioprine 3 (5) 6 (6)
Methotrexate 8 (14) 4 (4)
Mycophenolate Mofetil 0 (0) 0 (0)
Mean follow-up, years (SD) 2.1 (2.9) 2.24 (2.89)
Deaths, n 4 (6.8) 4 (4.3)
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alveolar volume (DLCO/VA) was significantly lower than
subjects in the non-PI group who performed the test
(mean ± SD) (71 ± 5.9% v 89 ± 7.23).
Discussion
AAV represents a very heterogeneous group of diseases
with disease-specific and overlapping clinical features
[6]. Although current therapies have reduced the rate of
mortality, the quality of life remains poor. Therefore, re-
cent studies to identify high-risk clinical features have
enhanced categorization of AAV using accurate stratifi-
cation for future therapeutic, epidemiological and basic
research [4,13].
BVAS and VDI are clinical tools that may provide an
accurate description of the current status of an individ-
ual patient in a standardized manner. Studies evaluating
long-term prognosis and risk factors have reported
organ-specific involvement as important indicators. GI
involvement at initial presentation in subjects with CSS
is associated with a high rate of relapse whilst the pres-
ences of renal disease and pANCA positivity are associ-
ated with lower rate of relapse [14]. Damage has been a
major concern with regard to patient outcome in AAV.
Since 1997, the VDI has been the only validated tool for
damage in AAV [15].
The role of LI at initial presentation remains contro-
versial [13]. A recent study with 80 subjects presenting
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with DAH in AAV showed that AAV was not associated
with increased deaths compared to renal insufficiency
[10]. In addition, ENT manifestations were associated
with a better outcome in GPA [11]. In a study with 155
subjects with GPA that were followed-up for a median
of 7 years, LI at diagnosis was predictive of a >3-fold
higher mortality [8]. Another study showed that DAH in
MPA was associated with 8.65 RR of mortality [7]. PI
was also a predictor of survival with renal involvement.
A later study by the same group showed that in 350 sub-
jects with renal AAV, lung and ENT involvement were
associated with RR of 1.7 for relapse [16]. The authors
postulated that the likelihood of pulmonary infection
and/or colonization is increased due to previous disease
activities leading to structural damages such as cavitating
lesions and further infection. This may lead to changes
in vascular flow trauma and adaptations responsible for
future relapses. External agents have been shown to in-
crease relapse such as nasal colonization with S. aureus
in GPA [17].
Our present study investigated the association of dam-
age and disease activity with PI at initial presentation in
subjects with AAV. There were no differences in BVAS3
and VDI between the PI and non-PI group. However,
when the subjects were subcategorized into LI and non-LI
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Figure 3 VDI scores at 2-year follow-up (f-VDI) in subjects
initially presenting with different pulmonary manifestations
(which may overlap). Data are represented as mean ± SEM. A
three-way ANOVA test was used to calculate differences between
the groups with a significance p-value cut-off of 0.05 (*p < 0.05,
**p < 0.01, ***p < 0.001).
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Figure 4 VDI scores at 2-year follow-up (f-VDI) in subjects
presenting initially with lung, pulmonary and non-pulmonary
manifestations diagnosed with different AAV phenotype. Data
are represented as mean ± SEM. A three-way ANOVA test was used
to calculate differences between the groups with a significance
p-value cut-off of 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
Table 3 Association between subjects with lung
invovlement and the presence of other pulmonary
complications within 2 years of follow-up, adjusted for age
and gender
Pulmonary complications OR (95% CI) P-value
Pulmonary hypertension 1.21 (0.92, 1.28) 0.082
Pulmonary fibrosis 1.79 (1.48, 2.12) <0.001
Pulmonary infarction 0.99 (0.91, 1.11) 0.222
Pleural fibrosis 1.13 (0.94, 1.21) 0.138
Chronic asthma 1.27 (1.12, 1.38) 0.072
FEV1/FVC ratio* 1.42 (1.27, 1.84) 0.045
DLCO/VA** 1.31 (1.22, 1.76) 0.045
*Ratio of forced expiratory volume in one second (FEV1) to force vital capacity
(FVC).
**Ratio of diffusing capacity of the lung for carbon monoxide (DLCO) to alveolar
volume (VA).
Table 2 Association between subjects with lung
invovlement and the presence of other vasculitis
manifestation as per BVAS 3 categories within 2 years of
follow-up adjusted for age and gender
Organ involvement OR (95% CI) P-value
General 1.32 (1.11, 1.59) 0.032
Skin/Mucous membrane 0.96 (0.91, 1.08) 0.280
Ocular 0.81 (0.69, 1.21) 0.637
Musculoskeletal 1.62 (1.15, 2.31) <0.001
Cardiovascular 1.31 (0.89, 1.54) 0.032
Peripheral vascular disease 1.01 (0.9, 1.28) 0.806
Gastrointestinal 0.99 (0.98, 1.13) 0.118
Renal 1.32 (1.22, 1.39) 0.005
Neuropsychiatric 1.00 (0.89, 1.11) 0.074
Other 1.14 (1.09, 1.19) 0.549
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groups, there were significant differences for both BVAS3
and VDI between the two groups at almost all time points.
It is to be noted that discrepancy of symptoms existed in
this study. 64% of subjects with PI were diagnosed with
GPA. Interestingly, the overall upper respiratory tract or
ENT involvement was less common at 20%. Tracheobron-
chial disease was also less common even though studies
have reported up to 50-60% [18,19]. This is likely due to
the design of the study which does not include subjects at-
tending the ENT service due to isolated upper respiratory
tract problems. In MPA, PI was not as common as GPA,
however half of these were diagnosed radiologically in
which radiographic infiltrates were the most common
finding. We had a smaller number of subjects presenting
with PI that were subsequently diagnosed with CSS. One
of these subjects had minor infiltrates on the presenting
chest radiograph. 2 subjects in the PI group were diag-
nosed with IPIPC in which one presented with limited al-
veolar hemorrhage. Therefore, we conclude that though
discrepancy of symptoms existed in this cohort, the preva-
lence of different diseases represent the overall prevalence
of these diseases in other AAV studies.
This is the first study evaluating BVAS3 in discriminat-
ing PI. The two main concerns flagged from BVAS ver-
sion 2 were that two sub-scores were produced to reflect
active and persistent disease respectively [20]. In BVAS3,
subjects with purely persistent disease will generate a
BVAS value on the same scale as those with ‘new/worse’
disease. The earlier BVAS2 has been shown to have
prognostic value and correlates with the validated 5-
factor prognostic score [21]. BVAS3 demonstrates
concordance with BVAS2, treatment decision, physician
global assessment and C-reactive protein [21], however,
further studies are required to determine if BVAS3 cor-
relates with mortality and/or health related quality of
life. We have shown here that BVAS3 correlates with
VDI. Accumulation of even a single VDI item is associ-
ated with reduced response to treatment and survival
[22]. A 6-month VDI score >4 has been associated with
increased risk of mortality [23].
We have not shown a correlation between PI and/or
LI with risk of relapses or mortality. This provides add-
itional data supporting recent studies looking at the low
impact of LI on the overall AAV prognosis. However,
the impact on the overall morbidity remained un-
answered. Interestingly, the BVAS and VDI have been
weakly correlated with patient health-related quality of
life (HRQOL) reinforcing that quality of life cannot be
generalized to biological effects of the disease only
[24,25]. Future studies should examine the effects of LI
in both physical and functional quality of life using ob-
jective assessment tools.
We showed a weak but statistically significant correl-
ation between PI and the presence of musculoskeletal,
renal and cardiovascular involvement within 2-years of
follow up. Renal involvement was expected due to the
high prevalence of pulmonary-renal syndrome in this co-
hort. Myalgia is included in the analysis of musculoskel-
etal involvement and therefore, may not impact on the
overall prognosis. However, cardiovascular involvement
was unexpected. This may relate to 4 and 6 subjects re-
spectively reported to have pulmonary hypertension and
coronary artery diseases in the PI group compared to 0
and 4 in the non-PI group respectively. Therefore, this
correlation could be related to the differences in preva-
lence of coronary artery disease that may or may not be
related to active vasculitis.
Interestingly, we also identified a significant relation-
ship between pulmonary fibrosis and AAV. Although
these parameters were recorded within 6 months to two
years of follow-up, we cannot determine that pulmonary
fibrosis is secondary to damage of previous lung involve-
ment or a new, unusual manifestation of AAV itself. A
few retrospective studies reported that pulmonary fibro-
sis is an underestimated manifestation of AAV, which
often predates the development of vasculitis [26,27].
There are several limitations to this study. The overall
number for specific diseases are small however, this
study emphasized the long-term impact of LI in AAV as
a single entity. Interestingly, there were differences in
VDI when subjects were subcategorized into disease-
specific populations, demonstrating that LI individuals
with GPA and MPA had higher VDI compared to their
counterparts. This observation could be mirrored due to
the partly distinct clinical manifestations which may re-
flect the differences between active vasculitis and granu-
lomatous inflammation. This reinforces the concept of
AAV especially in regards to MPA and GPA that are a
phenotypic continuum. Meanwhile, CS has distinct fea-
tures related to atopy and eosinophilia despite shared
features of pauci-immune glomerulonephritis and posi-
tive MPO-ANCA. AAV is recruited and those that were
may be selected leading to bias. For example, as subjects
were not recruited from all clinical services, other local-
ized forms of AAV such as localized cardiac or intracra-
nial vasculitis are not represented. Additionally, this
study did not take into account the possible effects of
different immunosuppressive regimens on damage scores
and complications.
Conclusions
Despite its limitations, this study is important as it high-
lights another issue in the natural history and prognosis
of AAV. Although the outcome of AAV has improved
significantly with the introduction of immunosuppressive
therapy, subsequent disease course remains unsatisfactory
for most subjects, due to low-grade active disease, relapse
and the effects of damage due to established disease or
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drug toxicity. This study shows that subjects presenting
with LI suffered considerable burden of disease which
should drive the search to improve current management
strategies in AAV. An important measure of future thera-
peutic approaches will be their ability to reduce the dam-
age accrued over time.
Additional file
Additional file 1: Figure S1. BVAS 3 scores at initial presentation. Data
were compared by non-parametric t-test (Mann Whitney U) with a
significance p-value cut-off of 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001).
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